NCT04222062 2025-02-27
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
University of Nebraska
Phase 2 Recruiting
Clinical Trials
13 trialsNCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT00003176 2018-06-27
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00086879 2017-07-27
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00004688 2015-03-25
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00005081 2014-08-21
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
Duke University
Phase 2 Completed
NCT00362921 2014-07-10
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
Duke University
Phase 2 Completed
NCT00006656 2013-11-06
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003878 2013-06-21
Carmustine Implants in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003467 2013-06-20
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00014573 2013-04-08
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00007982 2013-02-04
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00548938 2009-09-18
Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
Methodist Healthcare
Phase 2 Terminated